ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the expansion of its executive leadership team with Mark Przekop joining as Chief Operating Officer. As a veteran with over 35 years in the nuclear pharmacy and radiopharmaceuticals industry, Mark brings extensive commercial and operational experience in expanding supply chain networks, marketing and regulatory compliance oversight.
“Mark’s experience and wealth of knowledge in business strategy, commercial manufacturing, and supply chain oversight in radiopharmaceuticals, as demonstrated by his impressive background in nuclear medicine is a perfect fit for us,” said Charles S. Conroy, CEO of Nucleus RadioPharma. “Over the past year, we’ve reached major milestones, including closing our recent oversubscribed $56 million Series A to greatly increase the accessibility of radiopharmaceuticals to cancer patients, and we look forward to leveraging Mark’s expertise in business strategy to continue bringing life-saving treatments to patients with cancer.”
Prior to joining Nucleus, Mark held multiple roles at ARTMS, Inc., most recently as Chief Operating Officer responsible for overseeing supply chains for business operations, product development and chemistry teams, managing regulatory strategy for the ARTMS portfolio, and cultivating business partnerships with key U.S. nuclear pharmacy customers. He was also Vice President of Pharmacy Services at Jubilant Radiopharma, providing executive sales and operational support over the entire East Region, which included 26 radiopharmacies and PET manufacturing.
Please visit https://nucleusrad.com/#about for more information and to learn more about Nucleus RadioPharma’s partnering opportunities.
About Nucleus RadioPharma
Nucleus RadioPharma is a Contract Development and Manufacturing Organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies. Nucleus RadioPharma's mission is to ensure cancer patients can access potentially lifesaving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new treatment tools.